At this moment in the COVID-19 pandemic, we find ourselves at an inflection point. After several months of lockdown, we’re seeing nations, regions and municipalities begin to try to re-open their economies, while keeping a watchful eye on disease progression. Some countries are reopening while the infection rate continues to rise; others are moving with greater caution. Countries including South Korea, Lebanon and Germany are reintroducing lockdowns, after attempts to reopen led to more outbreaks. The U.S. is a patchwork, with widely different reactions and responses across the country.
Medidata is continuously monitoring the global impact of COVID-19 on clinical trials. In this paper see the impact of COVID-19 on patients, trials, read about the regulatory response, and learn about solutions available to assist sponsors/partners, patients and trials.